Newswire (Published: Tuesday, December 10, 2019, Received: Tuesday, December 10, 2019, 3:43:49 PM CST)

Word Count: 490

2019 DEC 10 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Researchers detail new data in Oncology - Prostate Cancer. According to news reporting originating in New York City, New York, by NewsRx journalists, research stated, “The SPARED CRN (Study of Prostate Ablation Related Energy Devices Coordinated Registry Network) is a private-public partnership between academic and community urologists, the FDA (U.S. Food and Drug Administration), the Medical Device Epidemiology Network and device manufacturers to examine the safety and effectiveness of technologies for partial gland ablation in men with localized prostate cancer.”

Financial support for this research came from New York Community Trust Frederick J. and Theresa Dow Wallace Fund.

The news reporters obtained a quote from the research from the Department of Urology, “We report on a recent workshop at the FDA with thought leaders to discuss a critical framework for partial gland ablation, focusing on patient selection, surgical planning, followup, study design and appropriate comparators in terms of adverse events and cancer control outcomes. We summarize salient points from experts in urology, oncology and epidemiology that were presented and discussed in an open forum. Given the challenges in achieving patient and physician equipoise to perform a randomized trial, as well as an inherent paradigm shift when comparing partial gland ablation (inability to assess prostate specific antigen recurrence) to whole gland treatments, the group focused on objective performance criteria and goals as a platform to guide the creation of single arm studies in the SPARED CRN.”

According to the news reporters, the research concluded: “This summit lays the foundation for prospective, multi-center data collection and evaluation of novel medical devices and drug/device combinations for partial gland ablation.”

For more information on this research see: Spared Collaboration: Patient Selection for Partial Gland Ablation In Men With Localized Prostate Cancer. The Journal of Urology, 2019;202(5):954-959. The Journal of Urology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

Our news correspondents report that additional information may be obtained by contacting J.C. Hu, New York Presbyterian Weill Cornell Med Coll, Dept. of Urology, New York, NY, United States. Additional authors for this research include M.D. Gross, A. Sedrakyan, B. Ehdaie, A.R. Rastinehad, J.S. Wysock, F.J. Bianco, P.R. Carroll, T.J. Daskivich, A.M. Priester, S.E. Eggener, B. Fisher, B. Hunt, H.Y. Jiang, D. Marinac-Dabic, C.J. Viviano, M.A. Gorin, E.A. Klein, J.S. Montgomery and T.J. Polascik.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/JU.0000000000000357. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

US Food and Drug Administration
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

North America
United States
Americas
New York
Pennsylvania
New York City
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology